Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review
Life Healthcare
On this page
Company details
- Legal name
- Life Healthcare Group Holdings Limited
- Incorporated in
- South Africa
- Listing
- LHC on the A2X Markets, active · ISIN ZAE000145892 (observed 2026-10-08)
- Sector
- Not classified (our classification from the stated principal activity)
- Financial year ends
- 30 September
Overview
Year ended 30 September 2025 · published summary of audited statements, final status not established · source
Read with these figures
- Published summary of audited statements not confirmed as final. The published copy is not confirmed as the final version. The FY to 30 Sep 2025 figures come from it.
Full wording and sources
Published summary of audited statements for 2025: final status not established
Published by the issuer inside its Integrated Annual Report 2025. No auditor's report on the summary is printed and the report holds no auditor's report; the Group AFS, with the independent auditor's report, are a separate publication (p6). The report states that the Group's AFS were independently audited by Deloitte & Touche and that the summarised financial information in the report was extracted from the audited AFS (p6). The Board approved the report on 4 December 2025; the approval names Dr Victor Litlhakanyane (Chairman) and Pete Wharton-Hood (Chief Executive) in type, with no visible signatures (PDF p6, page image).
Source: Life Healthcare Group Integrated Annual Report 2025 — Seven-year performance review (dated 2025-12-04)
2025, 2024: figures from a published summary
These columns come from a summary of the audited statements, not the full audited financial statements. 'Summarised financial information included in this report was extracted from the audited AFS.' (p6); the statements are printed in the appendix 'Seven-year performance review' (pp114-116). No auditor's report on the summary is printed. The report states (p6, 'In addition'): 'The Group's AFS were independently audited by our external auditors, Deloitte & Touche (Deloitte). Summarised financial information included in this report was extracted from the audited AFS.' No audit opinion is quoted. Appendix 'Seven-year performance review' (pp114-116): condensed group statement of comprehensive income (revenue, normalised EBITDA, operating result, net finance cost, associate, profit before tax and after tax from continuing operations, discontinued operations, profit for the year and its attribution; no expense lines, no income tax line, no other comprehensive income, no EPS), condensed statement of financial position (aggregated 'other' lines; no total liabilities) and condensed statement of cash flows (no investing or financing totals). Seven columns (2025-2019); only 2025 and 2024 are transcribed. No statement of changes in equity or notes.
Source: Life Healthcare Group Integrated Annual Report 2025 — Seven-year performance review (dated 2025-12-04)
-
Revenue
ZAR 25.1 billion
25,104 ZAR millions · p114
+6.0% vs 2024
-
Operating profit / (loss)
−ZAR 508 million
(508) ZAR millions · p114
Moved from profit to loss (FY to 30 Sep 2024: 2 320 ZAR millions)
-
Profit / (loss) for the year
ZAR 3.97 billion
3,971 ZAR millions · p114
−19.7% vs 2024
-
Total assets
ZAR 25.7 billion
25,690 ZAR millions · p115
+5.5% vs 2024
-
Total equity
ZAR 12.1 billion
12,142 ZAR millions · p115
−10.2% vs 2024
-
Cash from operations
ZAR 4.43 billion
4,425 ZAR millions · p116
+18.9% vs 2024
Large amounts are rounded for reading (ZAR million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.
Financial statements
Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in ZAR millions unless the row says otherwise; brackets are negative.
† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table
Column sources
- FY to 30 Sep 2025 — published summary of audited statements (summary), final status not established; reported for the year · source
- FY to 30 Sep 2024 — published summary of audited statements (summary), final status not established; comparative in the FY to 30 Sep 2025 filing · source
- 2025, 2024: figures from a published summary. These columns come from a summary of the audited statements, not the full audited financial statements. 'Summarised financial information included in this report was extracted from the audited AFS.' (p6); the statements are printed in the appendix 'Seven-year performance review' (pp114-116). No auditor's report on the summary is printed. The report states (p6, 'In addition'): 'The Group's AFS were independently audited by our external auditors, Deloitte & Touche (Deloitte). Summarised financial information included in this report was extracted from the audited AFS.' No audit opinion is quoted. Appendix 'Seven-year performance review' (pp114-116): condensed group statement of comprehensive income (revenue, normalised EBITDA, operating result, net finance cost, associate, profit before tax and after tax from continuing operations, discontinued operations, profit for the year and its attribution; no expense lines, no income tax line, no other comprehensive income, no EPS), condensed statement of financial position (aggregated 'other' lines; no total liabilities) and condensed statement of cash flows (no investing or financing totals). Seven columns (2025-2019); only 2025 and 2024 are transcribed. No statement of changes in equity or notes.
Income statement
| Line (as printed) | FY to 30 Sep 2025Published summary of audited statements (summary)reported for the year | FY to 30 Sep 2024Published summary of audited statements (summary)comparative in FY to 30 Sep 2025 filingsource limitations |
|---|---|---|
| Revenue from continuing operations | 25,104 | 23,674 |
| Operating (loss)/profit from continuing operations | (508) | 2,320 |
| Net finance cost1 | (122) | (158) |
| Share of associate's net profit after tax | 10 | 8 |
| (Loss)/profit before tax from continuing operations2 | (620) | 2,170 |
| (Loss)/profit for the year from continuing operations3 | (1,341) | 1,534 |
| Profit/(loss) from discontinued operation4 | 5,312 | 3,413 |
| Profit for the year | 3,971 | 4,947 |
| Non-controlling interest5 | 107 | 120 |
Notes and alternative reported figures (5)
- “Net finance cost” is an issuer-specific line, not mapped to a shared definition: Continuing operations; finance income less finance costs, one line.
- “(Loss)/profit before tax from continuing operations” is an issuer-specific line, not mapped to a shared definition: Continuing operations only; the income tax charge is not printed, so it does not reconcile to the after-tax line.
- “(Loss)/profit for the year from continuing operations” is an issuer-specific line, not mapped to a shared definition: After tax; the tax charge itself is not printed.
- “Profit/(loss) from discontinued operation” is an issuer-specific line, not mapped to a shared definition: AMG (2024) and LMI (2025) disposals.
- “Non-controlling interest” is an issuer-specific line, not mapped to a shared definition: Attribution of profit for the year.
Balance sheet
| Line (as printed) | FY to 30 Sep 2025Published summary of audited statements (summary)reported for the year | FY to 30 Sep 2024Published summary of audited statements (summary)comparative in FY to 30 Sep 2025 filingsource limitations |
|---|---|---|
| Property, plant and equipment | 11,301 | 10,765 |
| Intangible assets | 2,333 | 3,570 |
| Investment in associates and joint ventures | 47 | 104 |
| Employee benefit assets1 | 430 | 349 |
| Other non-current assets2 | 3,114 | 2,021 |
| Total non-current assets | 17,225 | 16,809 |
| Cash and cash equivalents | 3,810 | 2,462 |
| Trade and other receivables | 3,614 | 4,157 |
| Inventories | 408 | 466 |
| Other current assets3 | 633 | 207 |
| Total current assets | 8,465 | 7,292 |
| Assets classified as held for sale4 | –5 | 243 |
| Total assets | 25,690 | 24,344 |
| Capital and reserves6 | 11,377 | 12,539 |
| Non-controlling interest | 765 | 975 |
| Total shareholders' equity | 12,142 | 13,514 |
| Interest-bearing borrowings | 3,764 | 3,394 |
| Derivative financial instruments | –7 | –7 |
| Deferred tax liabilities | 1,937 | 1,492 |
| Other non-current liabilities8 | 801 | 674 |
| Total non-current liabilities | 6,502 | 5,560 |
| Bank overdraft | –9 | –9 |
| Trade and other payables | 3,811 | 3,910 |
| Interest-bearing borrowings | 187 | 1,027 |
| Other current liabilities10 | 3,048 | 318 |
| Total current liabilities | 7,046 | 5,255 |
| Liabilities directly associated with assets classified as held for sale11 | –12 | 15 |
| Total equity and liabilities | 25,690 | 24,344 |
- Printed “–”, read as nil: subtotal_arithmetic: bs.total_assets.
- Printed “–”, read as nil: subtotal_arithmetic: bs.non_current_liabilities.
- Printed “–”, read as nil: subtotal_arithmetic: bs.current_liabilities.
- Printed “–”, read as nil: subtotal_arithmetic: bs.total_equity_and_liabilities.
Notes and alternative reported figures (8)
- “Employee benefit assets” is an issuer-specific line, not mapped to a shared definition: Non-current assets.
- “Other non-current assets” is an issuer-specific line, not mapped to a shared definition: Non-current assets, aggregated by the issuer.
- “Other current assets” is an issuer-specific line, not mapped to a shared definition: Current assets, aggregated by the issuer.
- “Assets classified as held for sale” is an issuer-specific line, not mapped to a shared definition: 2025 printed '–'.
- “Capital and reserves”: mapping to a shared definition is uncertain. Printed 'Capital and reserves', before non-controlling interest: equity attributable to owners.
- “Other non-current liabilities” is an issuer-specific line, not mapped to a shared definition: Non-current liabilities, aggregated by the issuer.
- “Other current liabilities” is an issuer-specific line, not mapped to a shared definition: Current liabilities, aggregated by the issuer.
- “Liabilities directly associated with assets classified as held for sale” is an issuer-specific line, not mapped to a shared definition: 2025 printed '–'.
Cash flow
| Line (as printed) | FY to 30 Sep 2025Published summary of audited statements (summary)reported for the year | FY to 30 Sep 2024Published summary of audited statements (summary)comparative in FY to 30 Sep 2025 filingsource limitations |
|---|---|---|
| Cash generated from operations | 4,598 | 3,713 |
| Transaction costs paid1 | (17) | (11) |
| Interest received | 175 | 270 |
| Tax paid | (689) | (680) |
| Net cash generated from operating activities from discontinued operations2 | 358 | 431 |
| Net cash from operating activities | 4,425 | 3,723 |
| Net cash utilised in investing activities – investments to expand3 | (1,845) | (1,787) |
| Net cash generated from investing activities – disposals4 | 5,843 | 19,489 |
| Net cash generated from/(utilised in) investing activities – other5 | 41 | (272) |
| Net cash utilised in financing activities6 | (6,721) | (19,278) |
| Net cash utilised in investing activities from discontinued operations7 | (167) | (766) |
| Net cash utilised in financing activities from discontinued operations8 | (167) | (344) |
| Net increase/(decrease) in cash and cash equivalents | 1,409 | 765 |
| Cash and cash equivalents – beginning of the year | 1,862 | 659 |
| Effect of foreign exchange rate movements | (61) | (58) |
| Cash balances reclassified as held for sale9 | 600 | 1,096 |
| Cash and cash equivalents – end of the year | 3,810 | 2,462 |
Notes and alternative reported figures (9)
- “Transaction costs paid” is an issuer-specific line, not mapped to a shared definition: Operating activities.
- “Net cash generated from operating activities from discontinued operations” is an issuer-specific line, not mapped to a shared definition: Operating activities.
- “Net cash utilised in investing activities – investments to expand” is an issuer-specific line, not mapped to a shared definition: Investing activities (continuing).
- “Net cash generated from investing activities – disposals” is an issuer-specific line, not mapped to a shared definition: Investing activities (continuing).
- “Net cash generated from/(utilised in) investing activities – other” is an issuer-specific line, not mapped to a shared definition: Investing activities (continuing).
- “Net cash utilised in financing activities” is an issuer-specific line, not mapped to a shared definition: Financing activities of continuing operations; discontinued operations' financing is printed separately.
- “Net cash utilised in investing activities from discontinued operations” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Net cash utilised in financing activities from discontinued operations” is an issuer-specific line, not mapped to a shared definition: Financing activities.
- “Cash balances reclassified as held for sale” is an issuer-specific line, not mapped to a shared definition: Below the net change in cash.
Reported measures outside the statements
| Measure (as printed) | FY to 30 Sep 2025 | FY to 30 Sep 2024 |
|---|---|---|
| Normalised EBITDA1 from continuing operations | 3,845 p114 | 3,671 p114 |
Segments
Segment data not yet collected for this company in the pilot.
Dividends
Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.
No dividend statement or amount collected.
Sources
Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.
-
Life Healthcare Group Integrated Annual Report 2025 — Seven-year performance review
Year ended 30 September 2025 · Published summary of audited statements (summary) · final status not established
Audit: Deloitte & Touche (named); no auditor's opinion on the full statements in this document
Final status: Published by the issuer inside its Integrated Annual Report 2025. No auditor's report on the summary is printed and the report holds no auditor's report; the Group AFS, with the independent auditor's report, are a separate publication (p6). The report states that the Group's AFS were independently audited by Deloitte & Touche and that the summarised financial information in the report was extracted from the audited AFS (p6). The Board approved the report on 4 December 2025; the approval names Dr Victor Litlhakanyane (Chairman) and Pete Wharton-Hood (Chief Executive) in type, with no visible signatures (PDF p6, page image).
- Document date
- 4 Dec 2025
- Auditor's report
- date not recorded
- Board approval
- 4 Dec 2025
- Retrieved by us
- 8 Oct 2026 (not a publication date)
- Used for
- statement columns FY to 30 Sep 2025, FY to 30 Sep 2024
- Basis
- consolidated statements · ZAR millions (printed “R'm”)
- Cash flows (p116): the 2025 opening cash and cash equivalents (1 862) differ from the 2024 closing figure (2 462) by 600, the amount printed for 2025 as 'Cash balances reclassified as held for sale', which is added back below the net change; the summary does not explain the presentation. The checks cf.opening_equals_prior_closing and cf.opening_equals_balance_sheet at 30 September 2024 therefore fail (1 862 against 2 462); checked on the p116 render, kept as printed.
- The 2024 columns of the statement of comprehensive income (p114, '2024²') and the statement of cash flows (p116, '2024¹') carry the footnote 'Some figures are re-presented following the classification of AMG and LMI as discontinued operations'; those rows are marked restated.
- The summary is a multi-year performance review appendix of the Integrated Annual Report rather than a stand-alone results publication; provenance is stated (extracted from the audited AFS, board-approved report, p6). Transcribed as a summary; the controller should decide whether this tier is acceptable or whether the full Group AFS should be sought.
- No auditor's report on the summary is printed. The report states (p6, 'In addition'): 'The Group's AFS were independently audited by our external auditors, Deloitte & Touche (Deloitte). Summarised financial information included in this report was extracted from the audited AFS.' No audit opinion is quoted.
- Appendix 'Seven-year performance review' (pp114-116): condensed group statement of comprehensive income (revenue, normalised EBITDA, operating result, net finance cost, associate, profit before tax and after tax from continuing operations, discontinued operations, profit for the year and its attribution; no expense lines, no income tax line, no other comprehensive income, no EPS), condensed statement of financial position (aggregated 'other' lines; no total liabilities) and condensed statement of cash flows (no investing or financing totals). Seven columns (2025-2019); only 2025 and 2024 are transcribed. No statement of changes in equity or notes.
Technical details
- File
- 124 pages, with a text layer
- SHA-256
c300332a02c8abe03f4fe7d2b99c7a23bc984658c13795c4fec824fe6931ef2e- Entity as printed
- Life Healthcare Group Holdings Limited (Incorporated in the Republic of South Africa), Registration number: 2003/002733/06, ISIN: ZAE000145892 (PDF p122)
- Issuer copy
- retrieved 2026-10-08T18:45:33Z
Data notes
No figure-level notes beyond those in the tables.
Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.
Download
Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.
South Africa country page · Company methodology and coverage